Back to all press releases New York, NY – October 5, 2022 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data on TALEN®-edited smart CAR T-cel
Equities analysts predict that Cellectis S.A. (NASDAQ:CLLS – Get Rating) will announce earnings of ($0.55) per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Cellectis’ earnings. The lowest EPS estimate is ($0.85) and the highest is ($0.20). Cellectis reported earnings per share of ($0.88) in the same […]
Cellectis (NASDAQ:CLLS – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks.com reports. According to Zacks, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis […]
Shares of Cellectis S.A. (NASDAQ:CLLS – Get Rating) have earned a consensus rating of “Buy” from the nine brokerages that are covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokers […]
NEW YORK, May 16, 2022 Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today will present its first. | May 16, 2022